Medicine · Recorded milestone
Computationally designed drug reaches FDA review
Recorded year2026
After positive Phase 3 psoriasis results, Takeda reports FDA priority review for zasocitinib, a drug designed with computational chemistry. A decision is targeted for early 2027.
Explore this milestone on the interactive mapBuilt on
- Computational protein designRecorded · 2003influences
- AlphaFoldRecorded · 2020influences
Led to
- Zasocitinib wins FDA approvalForecast · ~2027requires
- AI-found antibiotic classesForecast · ~2032enables
- Drugs designed per patientForecast · ~2034enables
- Broad-spectrum antiviralsForecast · ~2035enables
- In-silico clinical trialsForecast · ~2040enables
- Universal biodefenceForecast · ~2045enables
- Mirror-image peptide drugsForecast · ~2060enables
Sources & evidence
- Takeda: FDA accepts zasocitinib application for priority review 2026-09-14
Takeda reports FDA acceptance of its psoriasis application after positive Phase 3 results, with a target decision in Q1 2027. Zasocitinib remains investigational; acceptance for review is not approval.
- Schrödinger and Nimbus: computational design of the TYK2 inhibitor
The design collaborators describe structure-based, physics-guided FEP+ discovery and optimization. This supports computational drug design; it does not establish that generative AI alone discovered the medicine.
Record reviewed 2026-10-18